Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Prostate Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 162 articles: HTML format

Single Articles

May 2021
1. KAWAMOTO K, Okino ST, Place RF, Urakami S, et al
   Editor's Note: Epigenetic Modifications of RASSF1A Gene through Chromatin Remodeling in Prostate Cancer.
   Clin Cancer Res. 2021;27:2665.
   PubMed    
   
   
   April 2021
2. TRUE LD, Chen DL
   How accurately does PSMA inhibitor 18F-DCFPyL-PET-CT image prostate cancer?
   Clin Cancer Res. 2021 Apr 23. pii: 1078-0432.CCR-21-0749.
   PubMed     Abstract available
   
   
   
3. PRIVE BM, Peters SMB, Muselaers CHJ, van Oort IM, et al
   Lutetium-177-PSMA-617 in low-volume hormone sensitive metastatic prostate cancer, a prospective pilot study.
   Clin Cancer Res. 2021 Apr 21. pii: 1078-0432.CCR-20-4298.
   PubMed     Abstract available
   
   
   
4. MCKAY RR, Kwak L, Crowdis J, Sperger JM, et al
   Phase 2 multicenter study of enzalutamide in metastatic castration resistant prostate cancer to identify mechanisms driving resistance.
   Clin Cancer Res. 2021 Apr 13. pii: 1078-0432.CCR-20-4616.
   PubMed     Abstract available
   
   
   March 2021
5. PACHYNSKI RK, Kim E, Miheecheva N, Kotlov N, et al
   Single cell spatial proteomic revelations on the multiparametric MRI heterogeneity of clinically significant prostate cancer.
   Clin Cancer Res. 2021 Mar 26. pii: 1078-0432.CCR-20-4217.
   PubMed     Abstract available
   
   
   
6. VARDAKI I, Corn P, Gentile E, Song JH, et al
   Radium 223 treatment increase immune checkpoint expression in extracellular vesicles from the metastatic prostate cancer bone microenvironment.
   Clin Cancer Res. 2021 Mar 22. pii: 1078-0432.CCR-20-4790.
   PubMed     Abstract available
   
   
   
7. PALMBOS PL, Daignault-Newton S, Tomlins SA, Agarwal N, et al
   A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone Sensitive Prostate Cancer (mHSPC).
   Clin Cancer Res. 2021 Mar 16. pii: 1078-0432.CCR-21-0024.
   PubMed     Abstract available
   
   
   
8. FREEDLAND SJ, Allen J, Jarman A, Oyekunle T, et al
   Correction: A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2).
   Clin Cancer Res. 2021;27:1823.
   PubMed    
   
   
   
9. KAMAT NV, Yu EY, Lee JK
   BiTE-ing into prostate cancer with bispecific T cell engagers.
   Clin Cancer Res. 2021 Mar 11. pii: 1078-0432.CCR-21-0355.
   PubMed     Abstract available
   
   
   February 2021
10. MORRIS MJ, Rowe SP, Gorin MA, Saperstein L, et al
    Diagnostic Performance of (18)F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study.
    Clin Cancer Res. 2021 Feb 23. pii: 1078-0432.CCR-20-4573.
    PubMed     Abstract available
    
    
    
11. PETRYLAK DP, Loriot Y, Shaffer D, Braiteh F, et al
    Safety and Clinical Activity of Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer: a Phase I Study.
    Clin Cancer Res. 2021 Feb 10. pii: 1078-0432.CCR-20-1981.
    PubMed     Abstract available
    
    
    
12. TUKACHINSKY H, Madison RW, Chung JH, Gjoerup O, et al
    Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms.
    Clin Cancer Res. 2021 Feb 8. pii: 1078-0432.CCR-20-4805.
    PubMed     Abstract available
    
    
    
13. LIANG Y, Jeganathan S, Marastoni S, Sharp A, et al
    Emergence of Enzalutamide resistance in prostate cancer is associated with BCL-2 and IKKB dependencies.
    Clin Cancer Res. 2021 Feb 4. pii: 1078-0432.CCR-20-3260.
    PubMed     Abstract available
    
    
    January 2021
14. DEEGEN P, Thomas O, Nolan-Stevaux O, Li S, et al
    The PSMA Targeting Half-Life Extended BiTE((R)) Therapy AMG 160 Has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2021 Jan 27. pii: 1078-0432.CCR-20-3725.
    PubMed     Abstract available
    
    
    
15. GOLDKORN A, Tangen CM, Plets M, Morrison GJ, et al
    Baseline circulating tumor cell count as a prognostic marker of PSA response and disease progression in metastatic castrate sensitive prostate cancer (SWOG S1216).
    Clin Cancer Res. 2021 Jan 26. pii: 1078-0432.CCR-20-3587.
    PubMed     Abstract available
    
    
    
16. PAN W, Zhang Z, Kimball H, Qu F, et al
    Abiraterone acetate induces CREB1 phosphorylation and enhances the function of the CBP-p300 complex, leading to resistance in prostate cancer cells.
    Clin Cancer Res. 2021 Jan 25. pii: 1078-0432.CCR-20-4391.
    PubMed     Abstract available
    
    
    
17. MARSHALL CH, Fu W, Wang H, Park JC, et al
    Randomized phase II trial of sipuleucel-T with or without radium-223 in men with bone-metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2021 Jan 15. pii: 1078-0432.CCR-20-4476.
    PubMed     Abstract available
    
    
    
18. VEACH D, Storey CM, Lueckerath K, Braun K, et al
    PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates.
    Clin Cancer Res. 2021 Jan 13. pii: 1078-0432.CCR-20-3614.
    PubMed     Abstract available
    
    
    December 2020
19. WANG S, Li J, Hua J, Su Y, et al
    Molecular imaging of prostate cancer targeting CD46 using immunoPET.
    Clin Cancer Res. 2020 Dec 8. pii: 1078-0432.CCR-20-3310.
    PubMed     Abstract available
    
    
    November 2020
20. LOTAN TL, Antonarakis ES
    CDK12 Deficiency and the Immune Microenvironment in Prostate Cancer.
    Clin Cancer Res. 2020 Nov 16. pii: 1078-0432.CCR-20-3877.
    PubMed     Abstract available
    
    
    
21. DELUCIA DC, Cardillo TM, Ang LS, Labrecque MP, et al
    Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer.
    Clin Cancer Res. 2020 Nov 16. pii: 1078-0432.CCR-20-3396.
    PubMed     Abstract available
    
    
    October 2020
22. AWASTHI S, Berglund AE, Abraham-Miranda J, Rounbehler RJ, et al
    Comparative genomics reveals distinct immune-oncologic pathways in African American men with prostate cancer.
    Clin Cancer Res. 2020 Oct 9. pii: 1078-0432.CCR-20-2925.
    PubMed     Abstract available
    
    
    
23. KARZAI F, Walker SM, Wilkinson S, Madan RA, et al
    Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-Risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is predictive of therapeutic response.
    Clin Cancer Res. 2020 Oct 6. pii: 1078-0432.CCR-20-2344.
    PubMed     Abstract available
    
    
    September 2020
24. CHEN WS, Haynes WA, Waitz R, Kamath K, et al
    Autoantibody landscape in patients with advanced prostate cancer.
    Clin Cancer Res. 2020 Sep 23. pii: 1078-0432.CCR-20-1966.
    PubMed     Abstract available
    
    
    
25. TRIPATHI A, Supko JG, Gray KP, Melnick Z, et al
    Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study of Concurrent Enzalutamide and Crizotinib.
    Clin Cancer Res. 2020 Sep 17. pii: 1078-0432.CCR-20-2306.
    PubMed     Abstract available
    
    
    
26. GAO AC, Armstrong CM, Liu C, Liu L, et al
    Steroid sulfatase stimulates intracrine androgen synthesis and is a therapeutic target for advanced prostate cancer.
    Clin Cancer Res. 2020 Sep 14. pii: 1078-0432.CCR-20-1682.
    PubMed     Abstract available
    
    
    
27. BORDINI J, Morisi F, Elia AR, Santambrogio P, et al
    Iron induces cell death and strengthens the efficacy of anti-androgen therapy in prostate cancer models.
    Clin Cancer Res. 2020 Sep 14. pii: 1078-0432.CCR-20-3182.
    PubMed     Abstract available
    
    
    August 2020
28. MUNIYAN S, Rachagani S, Parte S, Halder S, et al
    Sildenafil potentiates the therapeutic efficacy of docetaxel in advanced prostate cancer by stimulating NO-cGMP signaling.
    Clin Cancer Res. 2020 Aug 26. pii: 1078-0432.CCR-20-1569.
    PubMed     Abstract available
    
    
    
29. AUTIO KA, Klebanoff CA, Schaer DA, Kauh JS, et al
    Immunomodulatory Activity of a Colony-Stimulating Factor-1 Receptor Inhibitor in Patients With Advanced Refractory Breast or Prostate Cancer: A Phase 1 Study.
    Clin Cancer Res. 2020 Aug 26. pii: 1078-0432.CCR-20-0855.
    PubMed     Abstract available
    
    
    July 2020
30. SHENDEROV E, Antonarakis ES
    Reimagining vaccines for prostate cancer: Back to the future.
    Clin Cancer Res. 2020 Jul 31. pii: 1078-0432.CCR-20-2257.
    PubMed     Abstract available
    
    
    
31. GUAN X, Sun D, Lu E, Urrutia JA, et al
    Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2020 Jul 29. pii: 1078-0432.CCR-19-2303.
    PubMed     Abstract available
    
    
    
32. PARK SY, Na SJ, Kumar M, Mosci C, et al
    Clinical evaluation of (4S)-4-(3-[(18)F]Fluoropropyl)-L-glutamate ((18)F-FSPG) for PET/CT imaging in patients with newly diagnosed and recurrent prostate cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-0644.
    PubMed     Abstract available
    
    
    
33. AGGARWAL RR, Schweizer MT, Nanus DM, Pantuck AJ, et al
    A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-1707.
    PubMed     Abstract available
    
    
    
34. KAUR H, Salles DC, Murali S, Hicks JL, et al
    Genomic and Clinical-Pathologic Characterization of ATM-deficient Prostate Cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-0764.
    PubMed     Abstract available
    
    
    
35. HINTZ HM, Gallant JP, Vander Griend DJ, Coleman I, et al
    Imaging Fibroblast Activation Protein Alpha improves diagnosis of metastatic Prostate Cancer with Positron Emission Tomography.
    Clin Cancer Res. 2020 Jul 7. pii: 1078-0432.CCR-20-1358.
    PubMed     Abstract available
    
    
    June 2020
36. PALANISAMY N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, et al
    The MD Anderson prostate cancer patient-derived xenograft series (MDA PCa PDX) captures the molecular landscape of prostate cancer and facilitates marker-driven therapy development.
    Clin Cancer Res. 2020 Jun 23. pii: 1078-0432.CCR-20-0479.
    PubMed     Abstract available
    
    
    
37. PEREZ-RUIXO C, Ackaert O, Ouellet D, Chien C, et al
    Efficacy and safety exposure-response relationships of apalutamide in patients with non-metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2020 Jun 19. pii: 1078-0432.CCR-20-1041.
    PubMed     Abstract available
    
    
    
38. RAVI KUMAR AS, Hofman MS
    Mechanistic Insights for Optimizing PSMA Radioligand Therapy.
    Clin Cancer Res. 2020;26:2774-2776.
    PubMed     Abstract available
    
    
    
39. CURRENT K, Meyer C, Magyar CE, Mona CE, et al
    Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.
    Clin Cancer Res. 2020;26:2946-2955.
    PubMed     Abstract available
    
    
    
40. WANG B, Liu C, Wei Y, Meng J, et al
    A prospective trial of (68)Ga-PSMA and (18)F-FDG PET/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration.
    Clin Cancer Res. 2020 Jun 11. pii: 1078-0432.CCR-20-0587.
    PubMed     Abstract available
    
    
    
41. KYRIAKOPOULOS CE, Eickhoff J, Ferrari AC, Schweizer MT, et al
    Multicenter Phase 1 Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer.
    Clin Cancer Res. 2020 Jun 8. pii: 1078-0432.CCR-20-0945.
    PubMed     Abstract available
    
    
    May 2020
42. POSADAS EM, Chi KN, de Wit R, de Jonge MJA, et al
    Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase 1b Study.
    Clin Cancer Res. 2020 May 4. pii: 1078-0432.CCR-19-3402.
    PubMed     Abstract available
    
    
    April 2020
43. MALIHI PD, Graf RP, Rodriguez A, Ramesh N, et al
    Single-cell circulating tumor cell analysis reveals genomic instability as a distinctive feature of aggressive prostate cancer.
    Clin Cancer Res. 2020 Apr 27. pii: 1078-0432.CCR-19-4100.
    PubMed     Abstract available
    
    
    
44. MANDIGO AC, Knudsen KE
    Double Trouble: Concomitant RB1 and BRCA2 Depletion Evokes Aggressive Phenotypes.
    Clin Cancer Res. 2020;26:1784-1786.
    PubMed     Abstract available
    
    
    
45. BRAVE M, Weinstock C, Brewer JR, Chi DC, et al
    An FDA Review of Drug Development in Non-Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2020 Apr 13. pii: 1078-0432.CCR-19-3835.
    PubMed     Abstract available
    
    
    March 2020
46. SOKOLOVA AO, Yu EY, Cheng HH
    Honing in on PARPi response in Prostate Cancer: from HR pathway- to gene-by-gene granularity.
    Clin Cancer Res. 2020 Mar 31. pii: 1078-0432.CCR-20-0707.
    PubMed     Abstract available
    
    
    
47. STOPSACK KH, Nandakumar S, Wibmer AG, Haywood S, et al
    Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer.
    Clin Cancer Res. 2020 Mar 27. pii: 1078-0432.CCR-20-0168.
    PubMed     Abstract available
    
    
    
48. OBRADOVIC AZ, Dallos M, Zahurak ML, Partin AW, et al
    T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer.
    Clin Cancer Res. 2020 Mar 15. pii: 1078-0432.CCR-19-3372.
    PubMed     Abstract available
    
    
    
49. BHARGAVA HK, Leo P, Elliott R, Janowczyk A, et al
    Computationally Derived Image Signature of Stromal Morphology Is Prognostic of Prostate Cancer Recurrence Following Prostatectomy in African American Patients.
    Clin Cancer Res. 2020 Mar 5. pii: 1078-0432.CCR-19-2659.
    PubMed     Abstract available
    
    
    
50. WEI JJ, Wu X, Peng Y, Shi G, et al
    Editor's Note: Regulation of HMGA1 Expression by MicroRNA-296 Affects Prostate Cancer Growth and Invasion.
    Clin Cancer Res. 2020;26:1200.
    PubMed    
    
    
    February 2020
51. FREEDLAND SJ, Allen J, Jarman A, Oyekunle T, et al
    A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2).
    Clin Cancer Res. 2020 Feb 27. pii: 1078-0432.CCR-19-3873.
    PubMed     Abstract available
    
    
    
52. ABIDA W, Campbell D, Patnaik A, Shapiro JD, et al
    Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study.
    Clin Cancer Res. 2020 Feb 21. pii: 1078-0432.CCR-20-0394.
    PubMed     Abstract available
    
    
    
53. SZTUPINSZKI Z, Diossy M, Krzystanek M, Borcsok J, et al
    Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations.
    Clin Cancer Res. 2020 Feb 18. pii: 1078-0432.CCR-19-2135.
    PubMed     Abstract available
    
    
    January 2020
54. FAISAL FA, Murali S, Kaur H, Vidotto T, et al
    CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer.
    Clin Cancer Res. 2020 Jan 22. pii: 1078-0432.CCR-19-1669.
    PubMed     Abstract available
    
    
    
55. CORN PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, et al
    A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naive Metastatic Prostate Cancer.
    Clin Cancer Res. 2020 Jan 15. pii: 1078-0432.CCR-19-2389.
    PubMed     Abstract available
    
    
    
56. AGARWAL N, Nussenzveig RH, Hahn AW, Hoffman JM, et al
    Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2020 Jan 14. pii: 1078-0432.CCR-19-2591.
    PubMed     Abstract available
    
    
    
57. LI Y, Yang R, Henzler CM, Ho Y, et al
    Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer.
    Clin Cancer Res. 2020 Jan 13. pii: 1078-0432.CCR-19-3023.
    PubMed     Abstract available
    
    
    
58. NOURI M, Massah S, Caradec J, Lubik AA, et al
    Transient Sox9 Expression Facilitates Progression to Castrate Resistant Prostate Cancer.
    Clin Cancer Res. 2020 Jan 9. pii: 1078-0432.CCR-19-0098.
    PubMed     Abstract available
    
    
    
59. SCHWEIZER MT, Yu EY
    "Matching" the "mismatch" repair deficient prostate cancer with immunotherapy.
    Clin Cancer Res. 2020 Jan 3. pii: 1078-0432.CCR-19-3780.
    PubMed     Abstract available
    
    
    
60. SHANKAR S, Ganapathy S, Srivastava RK
    Editor's Note: Sulforaphane Enhances the Therapeutic Potential of TRAIL in Prostate Cancer Orthotopic Model through Regulation of Apoptosis, Metastasis, and Angiogenesis.
    Clin Cancer Res. 2020;26:312.
    PubMed    
    
    
    December 2019
61. HAMMER S, Hagemann UB, Zitzmann-Kolbe S, Larsen A, et al
    Preclinical efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC), a targeted alpha therapy for prostate cancer.
    Clin Cancer Res. 2019 Dec 12. pii: 1078-0432.CCR-19-2268.
    PubMed     Abstract available
    
    
    
62. CORELLA AN, Cabiliza Ordonio MVA, Coleman I, Lucas JM, et al
    Identification of Therapeutic Vulnerabilities in Small Cell Neuroendocrine Prostate Cancer.
    Clin Cancer Res. 2019 Dec 5. pii: 1078-0432.CCR-19-0775.
    PubMed     Abstract available
    
    
    
63. CHAKRABORTY G, Armenia J, Mazzu YZ, Nandakumar S, et al
    Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression.
    Clin Cancer Res. 2019 Dec 3. pii: 1078-0432.CCR-19-1570.
    PubMed     Abstract available
    
    
    
64. CHEN K, Cao Q, Song Z, Ruan H, et al
    Targeting the KIF4A/AR axis to reverse endocrine therapy resistance in castration-resistant prostate cancer.
    Clin Cancer Res. 2019 Dec 3. pii: 1078-0432.CCR-19-0396.
    PubMed     Abstract available
    
    
    November 2019
65. ALLOTT EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, et al
    Statin use is associated with lower risk of PTEN-null and lethal prostate cancer.
    Clin Cancer Res. 2019 Nov 21. pii: 1078-0432.CCR-19-2853.
    PubMed     Abstract available
    
    
    
66. RITCH E, Fu SYF, Herberts C, Wang G, et al
    Identification of hypermutation and defective mismatch repair in ctDNA from metastatic prostate cancer.
    Clin Cancer Res. 2019 Nov 19. pii: 1078-0432.CCR-19-1623.
    PubMed     Abstract available
    
    
    
67. GLUMAC PM, Gallant JP, Shapovalova M, Li Y, et al
    Exploitation of CD133 for the targeted imaging of lethal prostate cancer.
    Clin Cancer Res. 2019 Nov 15. pii: 1078-0432.CCR-19-1659.
    PubMed     Abstract available
    
    
    October 2019
68. TAGAWA ST, Antonarakis ES, Gjyrezi A, Galletti G, et al
    Clinical Significance of AR-V567es in Prostate Cancer-Response.
    Clin Cancer Res. 2019;25:6010-6011.
    PubMed    
    
    
    
69. UO T, Plymate SR
    Clinical Significance of AR-V567es in Prostate Cancer-Letter.
    Clin Cancer Res. 2019;25:6009.
    PubMed    
    
    
    September 2019
70. SPRATT DE, Alshalalfa M, Fishbane N, Weiner AB, et al
    Transcriptomic heterogeneity of androgen receptor (AR) activity defines a de novo low AR-active subclass in treatment naive primary prostate cancer.
    Clin Cancer Res. 2019 Sep 12. pii: 1078-0432.CCR-19-1587.
    PubMed     Abstract available
    
    
    
71. FENDLER WP, Weber M, Iravani A, Hofman MS, et al
    Prostate-Specific Membrane Antigen Ligand Positron-Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2019 Sep 11. pii: 1078-0432.CCR-19-1050.
    PubMed     Abstract available
    
    
    
72. PONNUSAMY S, He Y, Hwang DJ, Thiyagarajan T, et al
    Orally-Bioavailable Androgen Receptor Degrader, A Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
    Clin Cancer Res. 2019 Sep 3. pii: 1078-0432.CCR-19-1458.
    PubMed     Abstract available
    
    
    August 2019
73. LIU B, Li L, Yang G, Geng C, et al
    PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2019 Aug 22. pii: 1078-0432.CCR-19-0317.
    PubMed     Abstract available
    
    
    
74. BHAGIRATH D, Yang TL, Tabatabai ZL, Majid S, et al
    BRN4 is a novel driver of neuroendocrine differentiation in castration-resistant prostate cancer and is selectively released in extracellular vesicles with BRN2.
    Clin Cancer Res. 2019 Aug 1. pii: 1078-0432.CCR-19-0498.
    PubMed     Abstract available
    
    
    July 2019
75. BELTRAN H, Hruszkewycz A, Scher HI, Hildesheim J, et al
    The role of lineage plasticity in prostate cancer therapy resistance.
    Clin Cancer Res. 2019 Jul 30. pii: 1078-0432.CCR-19-1423.
    PubMed     Abstract available
    
    
    
76. KOTHARI V, Goodwin JF, Zhao SG, Drake JM, et al
    DNA-dependent protein kinase drives prostate cancer progression through transcriptional regulation of the Wnt signaling pathway.
    Clin Cancer Res. 2019 Jul 2. pii: 1078-0432.CCR-18-2387.
    PubMed     Abstract available
    
    
    May 2019
77. SLOVIN SF, Hussain S, Saad F, Garcia JA, et al
    Pharmacodynamic and clinical results from a phase 1/2 study of the HSP90 inhibitor onalespib in combination with abiraterone acetate in prostate cancer.
    Clin Cancer Res. 2019 May 21. pii: 1078-0432.CCR-18-3212.
    PubMed     Abstract available
    
    
    
78. KULP SK, Chen CS, Wang DS, Chen CY, et al
    Retraction: Antitumor Effects of a Novel Phenylbutyrate-based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer.
    Clin Cancer Res. 2019;25:2940.
    PubMed    
    
    
    April 2019
79. MAZZU YZ, Armenia J, Chakraborty G, Yoshikawa Y, et al
    A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2).
    Clin Cancer Res. 2019 Apr 17. pii: 1078-0432.CCR-18-4046.
    PubMed     Abstract available
    
    
    
80. WEST JB, Dinh MN, Brown JS, Zhang J, et al
    Multidrug cancer therapy in metastatic castrate-resistant prostate cancer: An evolution-based strategy.
    Clin Cancer Res. 2019 Apr 16. pii: 1078-0432.CCR-19-0006.
    PubMed     Abstract available
    
    
    
81. BERNEMANN C, Humberg V, Thielen B, Steinestel J, et al
    Comparative analysis of AR variant AR-V567es mRNA detection systems reveals eminent variability and questions the role as a clinical biomarker in prostate cancer.
    Clin Cancer Res. 2019 Apr 16. pii: 1078-0432.CCR-18-4276.
    PubMed     Abstract available
    
    
    
82. FERRARI AC, Alumkal JJ, Stein MN, Taplin ME, et al
    Correction: Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2019;25:2672.
    PubMed    
    
    
    
83. LIU YN, Niu S, Chen WY, Zhang Q, et al
    Leukemia inhibitory factor promotes castration-resistant prostate cancer and neuroendocrine differentiation by activated ZBTB46.
    Clin Cancer Res. 2019 Apr 8. pii: 1078-0432.CCR-18-3239.
    PubMed     Abstract available
    
    
    March 2019
84. KREGEL S, Malik R, Asangani IA, Wilder-Romans K, et al
    Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2019 Mar 27. pii: 1078-0432.CCR-18-3776.
    PubMed     Abstract available
    
    
    
85. REBELLO RJ, Oing C, Gillessen S, Bristow RG, et al
    TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?
    Clin Cancer Res. 2019;25:1699-1701.
    PubMed     Abstract available
    
    
    
86. DEHM SM, Montgomery B, Plymate SR
    AR-Variant-Positive CTC: A Surrogate for a Surrogate for Taxane Therapy Outcome?
    Clin Cancer Res. 2019;25:1696-1698.
    PubMed     Abstract available
    
    
    February 2019
87. BJARTELL A
    New hope in prostate cancer precision medicine? miRNA replacement and epigenetics.
    Clin Cancer Res. 2019 Feb 26. pii: 1078-0432.CCR-19-0061.
    PubMed     Abstract available
    
    
    
88. URABE F, Matsuzaki J, Yamamoto Y, Kimura T, et al
    Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer.
    Clin Cancer Res. 2019 Feb 26. pii: 1078-0432.CCR-18-2849.
    PubMed     Abstract available
    
    
    January 2019
89. MOHAMMADPOUR H, Bucsek MJ, Hylander BL, Repasky EA, et al
    Depression stresses the immune response and promotes prostate cancer growth.
    Clin Cancer Res. 2019 Jan 22. pii: 1078-0432.CCR-18-3980.
    PubMed     Abstract available
    
    
    
90. ZHANG M, Kobayashi N, Zettlitz KA, Kono EA, et al
    Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models.
    Clin Cancer Res. 2019;25:188-200.
    PubMed     Abstract available
    
    
    December 2018
91. BHATIA V, Yadav A, Tiwari R, Nigam S, et al
    Epigenetic silencing of miRNA-338-5p and miRNA-421 drives SPINK1-positive prostate cancer.
    Clin Cancer Res. 2018 Dec 26. pii: 1078-0432.CCR-18-3230.
    PubMed     Abstract available
    
    
    
92. MOSTAGHEL EA
    Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer.
    Clin Cancer Res. 2018 Dec 10. pii: 1078-0432.CCR-18-3410.
    PubMed     Abstract available
    
    
    November 2018
93. CHENG Y, Tang X, Li Y, Zhao D, et al
    Depression induced neuropeptide Y secretion promotes prostate cancer growth by recruiting myeloid cells.
    Clin Cancer Res. 2018 Nov 30. pii: 1078-0432.CCR-18-2912.
    PubMed     Abstract available
    
    
    October 2018
94. VAISHAMPAYAN U, Podgorski I, Heilbrun LK, Lawhorn-Crews JM, et al
    Biomarkers and Bone Imaging Dynamics associated with Clinical outcomes of Oral Cabozantinib Therapy in Metastatic Castrate Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Oct 16. pii: 1078-0432.CCR-18-1473.
    PubMed     Abstract available
    
    
    
95. GARRIDO MF, Martin NJ, Bertrand M, Gaudin C, et al
    Regulation of eIF4F translation initiation complex by the peptidyl prolyl isomerase FKBP7 in taxane-resistant prostate cancer.
    Clin Cancer Res. 2018 Oct 15. pii: 1078-0432.CCR-18-0704.
    PubMed     Abstract available
    
    
    
96. PAKARAINEN T, Nevalainen J, Talala K, Taari K, et al
    The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC).
    Clin Cancer Res. 2018 Oct 15. pii: 1078-0432.CCR-18-1807.
    PubMed     Abstract available
    
    
    
97. TAGAWA ST, Antonarakis ES, Gjyrezi A, Galletti G, et al
    Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY.
    Clin Cancer Res. 2018 Oct 9. pii: 1078-0432.CCR-18-0320.
    PubMed     Abstract available
    
    
    
98. FLORES-MORALES A, Bergmann TB, Lavallee C, Batth TS, et al
    Proteogenomic characterization of patient-derived xenografts highlights the role of REST in neuroendocrine differentiation of castration-resistant prostate cancer.
    Clin Cancer Res. 2018 Oct 1. pii: 1078-0432.CCR-18-0729.
    PubMed     Abstract available
    
    
    September 2018
99. NAVA RODRIGUES D, Casiraghi N, Romanel A, Crespo M, et al
    RB1 Heterogeneity in Advanced Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Sep 26. pii: 1078-0432.CCR-18-2068.
    PubMed     Abstract available
    
    
    
100. BELTRAN H, Oromendia C, Danila DC, Montgomery B, et al
     A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers.
     Clin Cancer Res. 2018 Sep 19. pii: 1078-0432.CCR-18-1912.
     PubMed     Abstract available
     
     
     
101. GAO X, Dai C, Huang S, Tang J, et al
     Functional silencing of HSD17B2 in prostate cancer promotes disease progression.
     Clin Cancer Res. 2018 Sep 18. pii: 1078-0432.CCR-18-2392.
     PubMed     Abstract available
     
     
     
102. FERRARI AC, Alumkal JJ, Stein MN, Taplin ME, et al
     Epigenetic Therapy with Panobinostat Combined with Bicalutamide Re-challenge in Castration-Resistant Prostate Cancer.
     Clin Cancer Res. 2018 Sep 17. pii: 1078-0432.CCR-18-1589.
     PubMed     Abstract available
     
     
     
103. DE LAERE B, Oeyen S, Mayrhofer M, Whitington T, et al
     TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.
     Clin Cancer Res. 2018 Sep 12. pii: 1078-0432.CCR-18-1943.
     PubMed     Abstract available
     
     
     
104. ZHANG T, George DJ, Armstrong AJ
     Precision medicine approaches when prostate cancer Akts up.
     Clin Cancer Res. 2018 Sep 11. pii: 1078-0432.CCR-18-2491.
     PubMed     Abstract available
     
     
     
105. KULARATNE SA, Thomas M, Myers CH, Gagare P, et al
     Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery for Prostate Cancer.
     Clin Cancer Res. 2018 Sep 10. pii: 1078-0432.CCR-18-0803.
     PubMed     Abstract available
     
     
     
106. ROSATI R, Polin LA, Ducker C, Li J, et al
     Strategy for Tumor Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
     Clin Cancer Res. 2018 Sep 5. pii: 1078-0432.CCR-18-0982.
     PubMed     Abstract available
     
     
     
107. SIPEKY C, Gao P, Zhang Q, Wang L, et al
     Synergistic interaction of HOXB13 and CIP2A predispose to aggressive prostate cancer.
     Clin Cancer Res. 2018 Sep 4. pii: 1078-0432.CCR-18-0444.
     PubMed     Abstract available
     
     
     
108. MOSTAGHEL EA, Zhang A, Hernandez S, Marck B, et al
     Contribution of Adrenal Glands to Intra-tumor Androgens and Growth of Castration Resistant Prostate Cancer.
     Clin Cancer Res. 2018 Sep 4. pii: 1078-0432.CCR-18-1431.
     PubMed     Abstract available
     
     
     August 2018
109. GRUBMULLER B, Baltzer PA, Hartenbach S, D'Andrea D, et al
     PSMA ligand PET/MRI for primary prostate cancer: Staging performance and clinical impact.
     Clin Cancer Res. 2018 Aug 23. pii: 1078-0432.CCR-18-0768.
     PubMed     Abstract available
     
     
     
110. LAMBROS MB, Seed G, Sumanasuriya S, Gil V, et al
     Single Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.
     Clin Cancer Res. 2018 Aug 9. pii: 1078-0432.CCR-18-0862.
     PubMed     Abstract available
     
     
     
111. GANAIE A, Beigh FH, Astone M, Ferrari MG, et al
     BMI1 drives metastasis of prostate cancer in Caucasian and African-American men and is a potential therapeutic target: hypothesis tested in race-specific models.
     Clin Cancer Res. 2018 Aug 7. pii: 1078-0432.CCR-18-1394.
     PubMed     Abstract available
     
     
     
112. BARBER LE, Gerke T, Markt SC, Peisch SF, et al
     Family history of breast or prostate cancer and prostate cancer risk.
     Clin Cancer Res. 2018 Aug 6. pii: 1078-0432.CCR-18-0370.
     PubMed     Abstract available
     
     
     
113. BOYSEN G, Nava Rodrigues D, Rescigno P, Seed G, et al
     SPOP mutated/ CHD1 deleted lethal prostate cancer and abiraterone sensitivity.
     Clin Cancer Res. 2018 Aug 1. pii: 1078-0432.CCR-18-0937.
     PubMed     Abstract available
     
     
     July 2018
114. IGLESIAS-GATO D, Thysell E, Tyanova S, Crnalic S, et al
     The proteome of prostate cancer bone metastasis reveals heterogeneity with prognostic implications.
     Clin Cancer Res. 2018 Jul 24. pii: 1078-0432.CCR-18-1229.
     PubMed     Abstract available
     
     
     
115. DE BONO JS, De Giorgi U, Nava Rodrigues D, Massard C, et al
     Randomized Phase II Study of Akt Blockade With or Without Ipatasertib in Abiraterone-Treated Patients With Metastatic Prostate Cancer With and Without PTEN Loss.
     Clin Cancer Res. 2018 Jul 23. pii: 1078-0432.CCR-18-0981.
     PubMed     Abstract available
     
     
     
116. TOREN P, Hoffman A, Ding K, Joncas FH, et al
     Serum sex steroids as prognostic biomarkers in patients receiving androgen deprivation therapy for recurrent prostate cancer: a post-hoc analysis of the PR.7 trial.
     Clin Cancer Res. 2018 Jul 18. pii: 1078-0432.CCR-18-1187.
     PubMed     Abstract available
     
     
     
117. ARAI S, Jonas O, Whitman M, Corey E, et al
     Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.
     Clin Cancer Res. 2018 Jul 18. pii: 1078-0432.CCR-18-0549.
     PubMed     Abstract available
     
     
     
118. LIU Q, Tong D, Liu G, Gao J, et al
     Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration.
     Clin Cancer Res. 2018 Jul 16. pii: 1078-0432.CCR-18-0420.
     PubMed     Abstract available
     
     
     
119. GUPTA S, Nordquist LT, Fleming MT, Berry WR, et al
     Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer.
     Clin Cancer Res. 2018 Jul 16. pii: 1078-0432.CCR-18-0564.
     PubMed     Abstract available
     
     
     
120. TANG W, Wallace TA, Yi M, Magi-Galluzzi C, et al
     IFNL4-DeltaG allele is associated with an interferon signature in tumors and survival of African-American men with prostate cancer.
     Clin Cancer Res. 2018 Jul 16. pii: 1078-0432.CCR-18-1060.
     PubMed     Abstract available
     
     
     June 2018
121. ANTONARAKIS ES, Small EJ, Petrylak D, Quinn DI, et al
     Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association With Overall Survival.
     Clin Cancer Res. 2018 Jun 1. pii: 1078-0432.CCR-18-0638.
     PubMed     Abstract available
     
     
     May 2018
122. BLEE AM, He Y, Yang Y, Ye Z, et al
     TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity in PTEN and TP53-mutated prostate cancer.
     Clin Cancer Res. 2018 May 29. pii: 1078-0432.CCR-18-0653.
     PubMed     Abstract available
     
     
     
123. HAYASHI T, Fujita K, Nojima S, Hayashi Y, et al
     High-fat Diet-induced Inflammation Accelerates Prostate Cancer Growth via IL6 Signaling.
     Clin Cancer Res. 2018 May 18. pii: 1078-0432.CCR-18-0106.
     PubMed     Abstract available
     
     
     
124. ALSHALALFA M, Karnes RJ, Sharma V, Choeurng V, et al
     Development and validation of a prostate cancer genomic signature that predicts early ADT treatment response following radical prostatectomy.
     Clin Cancer Res. 2018 May 14. pii: 1078-0432.CCR-17-2745.
     PubMed     Abstract available
     
     
     
125. 
     Correction: Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.
     Clin Cancer Res. 2018;24:2234.
     PubMed    
     
     
     
126. BHANVADIA RR, VanOpstall C, Brechka H, Barashi NS, et al
     MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease.
     Clin Cancer Res. 2018 May 1. pii: 1078-0432.CCR-17-3673.
     PubMed     Abstract available
     
     
     April 2018
127. HUANG H, Wang C, Liu F, Li HZ, et al
     Reciprocal Network between Cancer Stem-Like Cells and Macrophages Facilitates the Progression and Androgen Deprivation Therapy Resistance of Prostate Cancer.
     Clin Cancer Res. 2018 Apr 24. pii: 1078-0432.CCR-18-0461.
     PubMed     Abstract available
     
     
     
128. SHIH TC, Liu R, Wu CT, Li X, et al
     Targeting Galectin-1 impairs castration-resistant prostate cancer progression and invasion.
     Clin Cancer Res. 2018 Apr 17. pii: 1078-0432.CCR-18-0157.
     PubMed     Abstract available
     
     
     
129. GORDEVICIUS J, Krisciunas A, Groot DE, Yip SM, et al
     Cell-free DNA modification dynamics in abiraterone acetate-treated prostate cancer patients.
     Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-18-0101.
     PubMed     Abstract available
     
     
     March 2018
130. SCROGGINS B, Matsuo M, White A, Saito K, et al
     Hyperpolarized [1-(13)C]-pyruvate magnetic resonance spectroscopic imaging of prostate cancer in vivo predicts efficacy of targeting the Warburg effect.
     Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-1957.
     PubMed     Abstract available
     
     
     
131. WELTI J, Sharp A, Yuan W, Dolling DI, et al
     Targeting bromodomain and extra-terminal (BET) family proteins in castration resistant prostate cancer (CRPC).
     Clin Cancer Res. 2018 Mar 19. pii: 1078-0432.CCR-17-3571.
     PubMed     Abstract available
     
     
     February 2018
132. MARANTO C, Udhane V, Hoang DT, Gu L, et al
     STAT5A/B BLOCKADE SENSITIZES PROSTATE CANCER TO RADIATION THROUGH INHIBITION OF RAD51 AND DNA REPAIR.
     Clin Cancer Res. 2018 Feb 26. pii: 1078-0432.CCR-17-2768.
     PubMed     Abstract available
     
     
     
133. HECK MM, Retz M, Bandur M, Souchay M, et al
     Molecular lymph node status for prognostic stratification of prostate cancer patients undergoing radical prostatectomy with extended pelvic lymph node dissection.
     Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-3771.
     PubMed     Abstract available
     
     
     
134. KIM K, Watson PA, Lebdai S, Jebiwott S, et al
     Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
     Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-3474.
     PubMed     Abstract available
     
     
     November 2017
135. WANG C, Peng G, Huang H, Liu F, et al
     Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer.
     Clin Cancer Res. 2017 Nov 30. pii: 1078-0432.CCR-17-2446.
     PubMed     Abstract available
     
     
     
136. YANG Y, Bai Y, He Y, Zhao Y, et al
     PTEN loss promotes intratumoral androgen synthesis and tumor microenvironment remodeling via aberrant activation of RUNX2 in castration-resistant prostate cancer.
     Clin Cancer Res. 2017 Nov 22. pii: clincanres.2006.2017.
     PubMed     Abstract available
     
     
     
137. PUHR M, Hoefer J, Eigentler A, Ploner C, et al
     The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved anti-androgen therapy.
     Clin Cancer Res. 2017 Nov 20. pii: clincanres.0989.2017.
     PubMed     Abstract available
     
     
     
138. BELDERBOS BPS, Bins S, van Leeuwen RWF, Oomen-de Hoop E, et al
     Influence of Enzalutamide on Cabazitaxel Pharmacokinetics; a Drug-Drug Interaction Study in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients.
     Clin Cancer Res. 2017 Nov 17. pii: clincanres.2336.2017.
     PubMed     Abstract available
     
     
     
139. ZHANG W, Liu B, Wu W, Li L, et al
     Targeting the MYCN-PARP-DNA Damage Response Pathway inNeuroendocrine Prostate Cancer.
     Clin Cancer Res. 2017 Nov 14. pii: clincanres.1872.2017.
     PubMed     Abstract available
     
     
     
140. PALLER CJ, Zhou XC, Heath EI, Taplin ME, et al
     Muscadine Grape Skin Extract in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.
     Clin Cancer Res. 2017 Nov 7. pii: clincanres.1100.2017.
     PubMed     Abstract available
     
     
     September 2017
141. KALINA JL, Neilson DS, Lin YY, Hamilton PT, et al
     Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T cell Epitopes & Immune Signatures in a Subset of Prostate Cancer.
     Clin Cancer Res. 2017 Sep 27. pii: clincanres.0618.2017.
     PubMed     Abstract available
     
     
     
142. LABBE DP, Sweeney CJ, Brown M, Galbo P, et al
     TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup.
     Clin Cancer Res. 2017 Sep 12. pii: clincanres.0413.2017.
     PubMed     Abstract available
     
     
     
143. KETOLA K, Munuganti RS, Davies A, Nip KM, et al
     Targeting Prostate Cancer Subtype 1 by Forkhead box M1 Pathway Inhibition.
     Clin Cancer Res. 2017 Sep 12. pii: clincanres.0901.2017.
     PubMed     Abstract available
     
     
     
144. CALAGUA C, Russo J, Sun Y, Schaefer R, et al
     Expression of PD-L1 in Hormone-naive and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.
     Clin Cancer Res. 2017 Sep 11. pii: clincanres.0807.2017.
     PubMed     Abstract available
     
     
     August 2017
145. BELTRAN H, Wyatt AW, Chedgy E, Donoghue A, et al
     Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
     Clin Cancer Res. 2017 Aug 25. pii: clincanres.1034.2017.
     PubMed     Abstract available
     
     
     
146. GUEDES L, Antonarakis ES, Schweizer MT, Mirkheshti N, et al
     MSH2 Loss in Primary Prostate Cancer.
     Clin Cancer Res. 2017 Aug 8. pii: clincanres.0955.2017.
     PubMed     Abstract available
     
     
     July 2017
147. GAO WQ, Guo Y, Zhang K, Cheng C, et al
     Numb-/low enriches a castration resistant prostate cancer cell subpopulation associated with enhanced Notch and Hedgehog signaling.
     Clin Cancer Res. 2017 Jul 27. pii: clincanres.0913.2017.
     PubMed     Abstract available
     
     
     
148. SEED G, Yuan W, Mateo J, Carreira S, et al
     Gene Copy Number Estimation From Targeted Next Generation Sequencing Of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.
     Clin Cancer Res. 2017 Jul 27. pii: clincanres.0972.2017.
     PubMed     Abstract available
     
     
     
149. 
     Retraction: GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models.
     Clin Cancer Res. 2017;23:3973.
     PubMed    
     
     
     
150. 
     Correction: A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
     Clin Cancer Res. 2017;23:3970.
     PubMed    
     
     
     June 2017
151. BILUSIC M, Madan RA, Gulley JL
     Immunotherapy of Prostate Cancer: Facts and Hopes.
     Clin Cancer Res. 2017 Jun 29. pii: clincanres.0019.2017.
     PubMed     Abstract available
     
     
     
152. XU L, Mao X, Guo T, Chan PY, et al
     The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis.
     Clin Cancer Res. 2017 Jun 14. pii: clincanres.3081.2016.
     PubMed     Abstract available
     
     
     May 2017
153. BAN K, Feng S, Shao L, Ittmann M, et al
     RET signaling in prostate cancer.
     Clin Cancer Res. 2017 May 10. pii: clincanres.0528.2017.
     PubMed     Abstract available
     
     
     
154. KOHLI M, Ho Y, Hillman DW, Van Etten JL, et al
     Androgen receptor variant AR-V9 is co-expressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance.
     Clin Cancer Res. 2017 May 4. pii: clincanres.0017.2017.
     PubMed     Abstract available
     
     
     
155. MONTGOMERY B, Tretiakova MS, Joshua AM, Gleave ME, et al
     Neoadjuvant Enzalutamide Prior to Prostatectomy.
     Clin Cancer Res. 2017;23:2169-2176.
     PubMed     Abstract available
     
     
     April 2017
156. GUEDES L, Almutairi F, Haffner MC, Rajoria G, et al
     Analytic, Pre-analytic and Clinical Validation of p53 Immunohistochemistry for Detection of TP53 Missense Mutation in Prostate Cancer.
     Clin Cancer Res. 2017 Apr 26. pii: clincanres.0257.2017.
     PubMed     Abstract available
     
     
     
157. MOSTAGHEL EA, Cho E, Zhang A, Alyamani M, et al
     Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.
     Clin Cancer Res. 2017 Apr 7. pii: clincanres.2245.2016.
     PubMed     Abstract available
     
     
     
158. NIEUWEBOER AJ, de Graan AM, Hamberg P, Bins S, et al
     Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study.
     Clin Cancer Res. 2017;23:1679-1683.
     PubMed     Abstract available
     
     
     
159. NESBITT H, Byrne NM, Williams SN, Ming L, et al
     Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression.
     Clin Cancer Res. 2017;23:1797-1808.
     PubMed     Abstract available
     
     
     March 2017
160. SUOMINEN MI, Fagerlund KM, Rissanen JP, Konkol YM, et al
     Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models.
     Clin Cancer Res. 2017 Mar 31. pii: clincanres.2955.2016.
     PubMed     Abstract available
     
     
     January 2017
161. SINNOTT JA, Peisch SF, Tyekucheva S, Gerke T, et al
     Prognostic Utility of a New mRNA Expression Signature of Gleason Score.
     Clin Cancer Res. 2017;23:81-87.
     PubMed     Abstract available
     
     
     May 2016
162. CHUA ML, Bristow RG
     Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or <I>Frenemy</I>?
     Clin Cancer Res. 2016 May 10. pii: clincanres.0381.2016.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: